

Supplementary Materials for “No magic bullet: limiting in-school transmission in the face of variable SARS-CoV-2 viral loads”

Supplementary Text

S1: Children’s susceptibility and infectiousness

Early in the pandemic, there was a perception that children had reduced susceptibility to infection by SARS-CoV-2, based on studies conducted while children had lower contact rates than the general population^{1,2}. Rigorous meta-analyses do not support children’s reduced susceptibility to infection at this point¹. Consistent with this, studies with surveillance testing strategies report similar rates of infection between school-aged children and adults. For instance, in the UK (October 2020), the highest prevalence of SARS-CoV-2 infections in areas with open schools was in 18-25 year-olds, followed by 11-18 year-olds, with 5-11 year-olds having comparable prevalence to working-age adults³. At present, within the United States, the American Academy of Pediatrics⁴ estimates that greater than 1 in 10 children in the country has tested positive, and children comprised 19.0% of the cumulative reported COVID-19 cases (22.2% of the US population is under the age of 18).

The efficiency with which children transmit SARS-CoV-2 infections has also been debated- a key finding reported and cited often in the early debate about school reopening was that children were not usually the index case (first infection) within a family⁵, suggesting that children may not be responsible for disease spread. However, this finding is confounded with the lower likelihood of detection of asymptomatic index cases, and a number of studies (many of which rely on surveillance testing) point to children’s infectivity being similar^{6–10} or even higher^{11,12} than that of adults. Notably, similar infectivity between children and adults has been reported for variants of concern such as B.1.1.7¹³.

S2: Methodological issues with inferences regarding lack of transmission in school settings

The CDC’s science brief on the topic of in-school SARS-CoV-2 spread states that “the majority of cases that are acquired in the community and are brought into a school setting result in limited

spread inside schools when multiple layered prevention strategies are in place”¹⁴. This inference is based on two metrics.

The first metric is that rates of infection in schools and communities usually track each other closely, as has been reported in numerous studies worldwide. This correlation has been used inappropriately by the CDC and others^{15,16} to infer a lack of a causal relationship. In prior work¹⁷, we examined the validity of this inference by simulating a scenario where schools have a higher rate of SARS-CoV-2 transmission than the surrounding community and comparing it to a scenario where the rate of transmission was similar between schools and the community. We found that the ratio of cases between schools and community tracked closely even when schools were driving spread. This finding suggests that the correlation between caseloads in schools and communities is just as likely to be a result of in-school spread driving transmission within communities (cannot use correlation in case counts to infer a lack of causality). In prior work, we have demonstrated that transmission chains originating within schools are capable of generating large chains of spread within the community that can remain undetected in the absence of widespread surveillance testing¹⁸.

The second metric supporting the idea of limited spread in a school setting is that chains of transmission that can be clearly linked to in-school disease spread are rare. However, absence of evidence is not evidence of absence. Symptom-gated forward contact tracing (the method commonly used by schools in the US) to detect child-to-child transmission relies on the appearance and reporting of two consecutive symptomatic cases, connected by a transmission event (for example, see ¹⁶). Because the majority of transmission comes from a minority of cases (overdispersion)¹⁹ and children are more likely to experience asymptomatic infections than adults²⁰, symptom-gated forward contact tracing is expected to detect only 4.4% of all child-to-child transmission events in schools¹⁷.

In fact, this may point to a problem with symptom-gated forward contact tracing in general—recent contact-tracing studies in the United States suggest that many named contacts are not successfully traced^{21,22} and not all symptomatic contacts are willing to undergo testing²³.

Consistent with this, other events which may plausibly have led to rampant disease spread were not shown to have done so by symptom-gated forward contact tracing. As an example, consider

the case of the Sturgis motorcycle rally in August 2020, a 10-day event in Meade County, South Dakota attended by approximately 460,000 persons without any mask-wearing requirements or other mitigating policies. The event was followed by a wave of COVID-19 cases in Meade County and South Dakota in the month following the rally, and counties outside of South Dakota that contributed the highest inflows of rally attendees experienced a 6.4-12.5% increase in COVID-19 cases relative to counties without inflows²⁴. Despite clear evidence of population-level changes in COVID-19 case counts in the weeks following the rally, the CDC and Minnesota Department of Health were able to identify only 21 person-to-person transmission events²⁵. The methodology used for contact tracing was again, voluntary symptom-gated contact tracing. Out of the 86 positive cases, only 41 reported being in close contact (defined as being within 6 feet of another person for ≥ 15 minutes) with other people, and they reported an average of 2.5 close contacts. Both statistics are implausible for a 10-day motorcycle rally featuring indoor dining and concerts²⁶⁻²⁸. The CDC's report does not specify how many of the 102 secondary contacts were tested- this is also typical for contact-tracing studies in the United States^{21,22}.

Taken together, this suggests that the rarity of transmission chains in a given setting should be interpreted with caution if the methodology of contact tracing is not transparent, and if voluntary symptom-gated contact tracing methods are used.

S3: Evidence supporting the modeling assumption of aerosol spread of SARS-CoV-2

At this point, a robust body of evidence supports the assumption that SARS-CoV-2 spread occurs primarily through aerosol transmission.

First, efficient indoor transmission is more consistent with aerosol spread than it is with other modes of spread (such as ballistic droplets or surface transmission). In this context, the transmission rate for SARS-CoV-2 has been reported to be many (~19-40) times higher indoors than it is outdoors^{29,30}. There is also direct evidence for long-range transmission indoors^{31,32}, even in cases where people were in adjacent rooms³³ or in rooms separated by a corridor³⁴.

despite never have been in each other's presence. Modeling suggests that long-range transmission may also occur outdoors³⁵.

Second, infectious virus has been isolated from a number of locations that are consistent with aerosol spread. A number of groups have reported direct isolation of infectious virus from the air³⁶⁻³⁸, in air filters and building ducts³⁹, as well as in exhaled aerosols⁴⁰.

Third, epidemiological characteristics of SARS-CoV-2 are consistent with aerosol transmission. For example, aerosol spread provides a direct mechanistic basis for superspreader transmission⁴¹, which has been well documented for SARS-CoV-2¹⁹. Asymptomatic transmission from people who are not coughing or sneezing – another extensively documented feature of SARS-CoV-2 - is also consistent with aerosol transmission^{42,43}.

There are a number of excellent overviews on the topic of aerosol spread of SARS-CoV-2^{44,45}. The data supporting aerosol transmission of SARS-CoV-2 was also put forth in an open letter to the WHO⁴⁶, which the WHO initially contested in a scientific brief⁴⁷ before grudgingly accepting⁴⁸. It is worth noting that the propensity for aerosol transmission seems to be impacted by evolution as well- for example, the Alpha variant of SARS-CoV-2 has been experimentally shown to be better able to spread via aerosol transmission than the ancestral strain⁴⁹.

S4: Evidence supporting the modeling assumption of the room as a well-mixed container

In this work we started with the well-mixed assumption for air flow. This initial assumption is justified from two different lines of evidence.

Physics-based considerations: The current state of evidence suggests a very strong contribution of aerosol particles to the spread of SARS-CoV-2 (summarized in the preceding section). In the context of this work, we have considered particles to be aerosolized if their diameters are in the range of 0.1-30 microns in diameter. For particles in this size range, the rate of spread due to diffusion or Brownian motion is negligible relative to the rate of spread due to air flow. The spread of such particles emitted by an unmasked individual due to speaking⁵⁰, coughing or sneezing⁵¹ would be primarily expected to occur due to the horizontal momentum of exhaled air

particles, with a minimal contribution from gravity-induced drift⁵². However, in the presence of masks, the horizontal movement of exhaled air is greatly suppressed, and instead the particles rise due to turbulent buoyant airflow⁵³. The Reynolds number (Re) determines the behavior of air flow with a given speed and length scale, with moderately high Re s (>100) associated with vortex shedding, and still higher Re s (>2000) associated with turbulent flow. In the presence of forced convection within a room (such as can be expected from air circulation or ventilation), Re can be expected to be fairly high (≈ 2000), corresponding to a mix of vortex shedding and turbulent flows⁵⁴. Additional factors can also contribute to turbulence, such as human movement.

Epidemiological considerations: A number of epidemiological studies also support the well-mixed-container assumption. Indoor transmission has been demonstrated to occur in a wide variety of settings at ranges that were likely greater than 6 feet apart^{31,32,55}. A notable example of this was the Skagit Valley Chorale superspreader event, where a weekly rehearsal with 61 masked attendees led to 53 infections— a model-based analysis of this event has argued that the outcome supports the well-mixed assumption empirically⁴². Also consistent with the well-mixed assumption is the finding that transmission occurs 19 times more efficiently indoors²⁹.

The well-mixed assumption is implemented in our modeling using the Wells-Riley approach, first proposed by Wells⁵⁶ in 1955 and extended by Riley⁵⁷ in 1978. This approach has been found to be broadly applicable for indoor air transmission for other infectious respiratory diseases⁵⁸, and has been used to model SARS-CoV-2 transmission by a number of other groups⁵⁹.

S5: Estimates for variation in viral load between viral variants and individuals infected with SARS-CoV-2

In this study, we have used the Delta variant as an example of a SARS-CoV-2 viral strain with increased viral load, to exemplify the impact of viral load on guidelines for preventing transmission. The increased transmission rate of the Delta strain relative to prior SARS-CoV-2 variants has been at least partly attributed to a higher viral load in the nasopharynx. Studies have found RT-qPCR cycle threshold values for Delta that are approximately 6-1000 times higher

than prior variants. We note that there is a range of estimates for relative viral load for the Delta variant compared to other variants (see table below).

Wide person-to-person variation in exhaled viral load have also been reported for SARS-CoV-2 infections based on intrinsic factors as well as on the specific activity being undertaken⁶⁰.

Relative viral load of Delta	Variant compared	Reference
6.06 times greater	Alpha	61
11.48 times greater	Pre-Alpha	62
1260 times greater	Pre-Alpha	63

Incubation times also vary between different SARS-CoV-2 variants. The incubation period for the original Wuhan strain is around 5 days^{64,65} while the Delta incubation is shorter (4.3 days⁶⁴). The Omicron variant has an even shorter incubation period, estimated at approximately 3 days⁶⁶.

S6: Parameters governing the efficacy of individual control measures

Air filtration:

High-efficiency particulate air (HEPA) filters are defined by the US Environmental Protection Agency to remove at least 99.97% of airborne particles for all particle sizes⁶⁷. These filters can be installed in small mobile or large floor-standing air purifiers, which can ideally exchange 5 to 6 times the air volume in the room per hour^{68,69}. A standard mobile air purification setup in a classroom has been shown experimentally to reduce airborne viral concentrations by 90% within approximately 30 minutes⁶⁹.

Ionizers:

Bipolar air ionizers create an electrostatic charge on airborne particles, causing them to be removed from the air by increasing their aggregation rate and deposition rate on surfaces⁷⁰. Smoke particle studies suggest that ionizers can remove between 80-100% of particles from room air⁷¹⁻⁷³.

Masks:

Face masks have been shown to lower the risk of SARS-CoV-2 transmission⁷⁴ by both reducing the number of virions emitted by infected individuals and reducing the amount of virus inhaled by uninfected individuals who are masked. Cloth and surgical masks have typical filtration efficiencies of around 20-95% for droplets or aerosols, with cloth masks having lower efficiencies (20-75% particles filtered out) for smaller particles sizes (0.3-0.5um)⁷⁵. N95 and KN95 respirators are rated to remove 95% or more of 0.3um particles⁷⁶.

S7: Estimates for minimum infectious dose for SARS-CoV-2

For the ancestral Wuhan strain of SARS-CoV-2, estimates of infectious dose have been made by diverse methods including CFD modeling⁷⁷ and phylogenetic analysis⁷⁸. These estimates point to a small number of infectious particles - 6⁷⁸ to 300⁷⁷ - being sufficient to start an infection. The upper end of this range is similar to the infectious dose for SARS-CoV⁷⁹, and an order of magnitude lower than that of influenza⁸⁰. Here, we used 500 virions as the minimum infectious dose, which is on the upper end of the published range. Estimates of infectious dose for novel variants such as Delta have been a further order of magnitude lower, with some reports suggesting that fewer than ten viral particles may be sufficient to start an infection^{63,81,82}.

S8: Performance of vaccines in limiting transmission of SARS-CoV-2

Vaccines against SARS-CoV-2 currently possess high levels of efficacy in preventing severe disease and death from COVID-19⁸³ and form a critical last line of defense in the public-health strategy. Vaccinal efficacy against severe disease appears somewhat stable over time, which some have suggested is linked to T-cell activity⁸⁴.

The impact of vaccines in limiting infection and transmission appears to be dependent on humoral immunity⁸⁵, and this impact appears more limited and time-dependent. Estimating the impact of SARS-CoV-2 vaccines on transmission (VE_t) is challenging, because many vaccine trials did not directly assess vaccine efficacy against transmission, focusing instead on symptomatic infections. As a substantial portion of SARS-CoV-2 infected patients are infectious

while asymptomatic⁸⁶ or presymptomatic⁸⁷ and this proportion rises with breakthrough infections^{88–90}, estimates for vaccinal efficacy against transmission are biased when considering only symptomatic infections in the denominator^{91,92}. Despite this overestimation bias for VE_t , recent reports point to a very low degree of vaccinal efficacy against symptomatic disease in some circumstances⁹³. This suggests that VE_t is even lower and may in some settings be negligible.

Humoral immunity wanes shortly after vaccination, as neutralizing antibodies (nAbs) decline rapidly after the second dose^{94,95}, with a mean half-life of about four months⁹⁶. Consistent with this decline in nAb levels, waning vaccinal immunity against infection has been documented extensively, with substantial loss of protection against infection occurring within the first six months^{97,98}. While this efficacy against symptomatic infection is restored by booster doses, booster efficacy also declines rapidly⁹³.

Viral evolution is a second contributing factor to the loss of vaccinal immunity. Viral immune evasion has also been demonstrated to potentially reduce the ability of neutralizing antibodies (nAbs) to bind SARS-CoV-2 spike protein - for example, the Omicron variant shows a profound (20-40 fold) reduction in the binding potency of nAbs against the viral spike protein^{99–102}. Consistent with this, vaccinal efficacy against symptomatic infection with Omicron is severely compromised- for example, for individuals vaccinated with two doses of the Pfizer vaccine, VE against infection is 8.8% (95% CI, 7.0 to 10.5) at 25 or more weeks⁹³. Other viral variants have also demonstrated substantial reductions in nAb binding potency^{103–105} and vaccinal immunity against infection^{106,107}. A number of studies have pointed to a predictive relationship between nAb binding potency and vaccinal protection against infection^{85,96}.

In addition, the impact of vaccination on onward transmission by infected individuals has also been found to be modest. Some reports from earlier in the pandemic indicated a 50% reduction in infectiousness associated with vaccine breakthrough cases with the Wuhan strain¹⁰⁸. However, the reduction in viral load for breakthrough cases is minimal for recent variants such as Delta^{85,109–111} and Omicron¹¹². For these variants, epidemiological data is also consistent with a picture of efficient transmission by breakthrough cases- the secondary attack rate for infection resulting from a vaccinal breakthrough case is only marginally lower than that of unvaccinated

individuals for Delta^{109,110} and Omicron¹¹³. Multiple real-world examples of superspreader events¹¹⁴ and ongoing spread¹¹⁵ among highly vaccinated populations add further weight to the inference of limited impact of vaccination on curbing SARS-CoV-2 spread. Going forward, continued viral evolution and waning vaccinal effectiveness¹¹⁶ in reducing viral load (which has now been noted for the booster dose as well^{117,118} can be further expected to impact the vaccinal reduction of transmission.

In summary, these findings support the assumption that vaccination status does not contribute significantly to the ability of an individual to contract or transmit SARS-CoV-2 in a congregate setting.

References for supplemental materials

1. Davies, N. G. *et al.* Age-dependent effects in the transmission and control of COVID-19 epidemics. *Nat Med* **26**, 1205–1211 (2020).
2. Viner, R. M. *et al.* Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults: A Systematic Review and Meta-analysis. *JAMA Pediatrics* **175**, 143–156 (2021).
3. Flasche, S. & Edmunds, W. J. The role of schools and school-aged children in SARS-CoV-2 transmission. *Lancet Infect Dis* **21**, 298–299 (2021).
4. American Academy of Pediatrics. Children and COVID-19: State-Level Data Report. *American Academy of Pediatrics* <http://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/> (2022).
5. Zhu, Y. *et al.* A Meta-analysis on the Role of Children in Severe Acute Respiratory Syndrome Coronavirus 2 in Household Transmission Clusters. *Clin Infect Dis* **72**, e1146–e1153 (2021).
6. Lopez, A. S. *et al.* Transmission Dynamics of COVID-19 Outbreaks Associated with Child Care Facilities — Salt Lake City, Utah, April–July 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 1319–1323 (2020).
7. Laxminarayan, R. *et al.* Epidemiology and transmission dynamics of COVID-19 in two Indian states. *Science* **370**, 691–697 (2020).
8. Grijalva, C. G. *et al.* Transmission of SARS-COV-2 Infections in Households — Tennessee and Wisconsin, April–September 2020. *MMWR Morb Mortal Wkly Rep* **69**, 1631–1634 (2020).

9. Park, Y. J. *et al.* Contact Tracing during Coronavirus Disease Outbreak, South Korea, 2020. *Emerging Infectious Diseases* **26**, (2020).
10. Yonker, L. M. *et al.* Virologic Features of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Children. *The Journal of Infectious Diseases* **224**, 1821–1829 (2021).
11. Paul, L. A. *et al.* Association of Age and Pediatric Household Transmission of SARS-CoV-2 Infection. *JAMA Pediatrics* **175**, 1151–1158 (2021).
12. Heald-Sargent, T. *et al.* Age-Related Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease 2019 (COVID-19). *JAMA Pediatrics* **174**, 902–903 (2020).
13. Loenenbach, A. *et al.* SARS-CoV-2 variant B.1.1.7 susceptibility and infectiousness of children and adults deduced from investigations of childcare centre outbreaks, Germany, 2021. *Eurosurveillance* **26**, (2021).
14. CDC. Science Brief: Transmission of SARS-CoV-2 in K-12 Schools and Early Care and Education Programs. *Centers for Disease Control and Prevention*
https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/transmission_k_12_schools.html (2021).
15. Ertem, Z. *et al.* The impact of school opening model on SARS-CoV-2 community incidence and mortality. *Nat Med* **27**, 2120–2126 (2021).
16. Falk, A. *et al.* COVID-19 Cases and Transmission in 17 K-12 Schools - Wood County, Wisconsin, August 31-November 29, 2020. *MMWR Morb Mortal Wkly Rep* **70**, 136–140 (2021).
17. Johnson, K. E. *et al.* Detecting in-school transmission of SARS-CoV-2 from case ratios and documented clusters. 2021.04.26.21256136 (2021) doi:10.1101/2021.04.26.21256136.

18. Johnson, K. E. *et al.* In the long shadow of our best intentions: Model-based assessment of the consequences of school reopening during the COVID-19 pandemic. *PLoS One* **16**, e0248509 (2021).
19. Endo, A., Abbott, S., Kucharski, A. J. & Funk, S. Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China. *Wellcome Open Res* **5**, 67 (2020).
20. Dawood, F. S. *et al.* Incidence Rates, Household Infection Risk, and Clinical Characteristics of SARS-CoV-2 Infection Among Children and Adults in Utah and New York City, New York. *JAMA Pediatrics* **176**, 59–67 (2022).
21. McClain, C. & Rainie, L. The Challenges of Contact Tracing as U.S. Battles COVID-19. *Pew Research Center* <https://www.pewresearch.org/internet/2020/10/30/the-challenges-of-contact-tracing-as-u-s-battles-covid-19/> (2020).
22. Hendrix, M. J., Walde, C., Findley, K. & Trotman, R. Absence of Apparent Transmission of SARS-CoV-2 from Two Stylists After Exposure at a Hair Salon with a Universal Face Covering Policy - Springfield, Missouri, May 2020. *MMWR Morb Mortal Wkly Rep* **69**, 930–932 (2020).
23. Doyle, T. *et al.* COVID-19 in Primary and Secondary School Settings During the First Semester of School Reopening — Florida, August–December 2020. *MMWR Morb. Mortal. Wkly. Rep.* **70**, 437–441 (2021).
24. Dave, D., McNichols, D. & Sabia, J. J. The contagion externality of a superspreading event: The Sturgis Motorcycle Rally and COVID-19. *South Econ J* (2020) doi:10.1002/soej.12475.

25. Firestone, M. J. *et al.* COVID-19 Outbreak Associated with a 10-Day Motorcycle Rally in a Neighboring State — Minnesota, August–September 2020. *MMWR Morb. Mortal. Wkly. Rep.* **69**, 1771–1776 (2020).
26. Rapier, G. ‘If I die from the virus, it was just meant to be’: 250,000 descend upon tiny South Dakota town for world-famous motorcycle rally. *Business Insider* <https://www.businessinsider.com/sturgis-motorcycle-rally-kicks-off-despite-surgin-coronavirus-cases-2020-8> (2020).
27. Associated Press. Harleys everywhere, masks nowhere: Sturgis expects crowd of 250,000. *Chicago Sun-Times* <https://chicago.suntimes.com/coronavirus/2020/8/7/21359318/sturgis-motorcycle-harleys-everywhere-masks-nowhere> (2020).
28. 2020 Sturgis Motorcycle Rally attracts thousands with no mask requirements amid pandemic. *USA Today* <https://www.usatoday.com/picture-gallery/news/nation/2020/08/09/2020-sturgis-motorcycle-rally-draws-thousands-no-mask-requirements-covid-19-coronavirus/3331908001/> (2020).
29. Bulfone, T. C., Malekinejad, M., Rutherford, G. W. & Razani, N. Outdoor Transmission of SARS-CoV-2 and Other Respiratory Viruses: A Systematic Review. *The Journal of Infectious Diseases* **223**, 550–561 (2021).
30. Nishiura, H. *et al.* Closed environments facilitate secondary transmission of coronavirus disease 2019 (COVID-19). 2020.02.28.20029272 (2020) [doi:10.1101/2020.02.28.20029272](https://doi.org/10.1101/2020.02.28.20029272).
31. Ou, C. *et al.* Insufficient ventilation led to a probable long-range airborne transmission of SARS-CoV-2 on two buses. *Building and Environment* **207**, 108414 (2022).

32. Lu, J. *et al.* COVID-19 Outbreak Associated with Air Conditioning in Restaurant, Guangzhou, China, 2020. *Emerg Infect Dis* **26**, 1628–1631 (2020).
33. Eichler, N. *et al.* Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 during Border Quarantine and Air Travel, New Zealand (Aotearoa). *Emerg Infect Dis* **27**, 1274–1278 (2021).
34. Fox-Lewis, A. *et al.* Airborne Transmission of SARS-CoV-2 Delta Variant within Tightly Monitored Isolation Facility, New Zealand (Aotearoa). *Emerg Infect Dis* **28**, 501–509 (2022).
35. Gorbunov, B. Aerosol Particles Generated by Coughing and Sneezing of a SARS-CoV-2 (COVID-19) Host Travel over 30 m Distance. *Aerosol Air Qual. Res.* **21**, 200468 (2021).
36. van Doremalen, N. *et al.* Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. *New England Journal of Medicine* **382**, 1564–1567 (2020).
37. Lednicky, J. A. *et al.* Viable SARS-CoV-2 in the air of a hospital room with COVID-19 patients. *International Journal of Infectious Diseases* **100**, 476–482 (2020).
38. Lednicky, J. A. *et al.* Isolation of SARS-CoV-2 from the air in a car driven by a COVID patient with mild illness. *International Journal of Infectious Diseases* **108**, 212–216 (2021).
39. Nissen, K. *et al.* Long-distance airborne dispersal of SARS-CoV-2 in COVID-19 wards. *Sci Rep* **10**, 19589 (2020).
40. Adenaiye, O. O. *et al.* Infectious Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Exhaled Aerosols and Efficacy of Masks During Early Mild Infection. *Clinical Infectious Diseases* ciab797 (2021) doi:10.1093/cid/ciab797.
41. Lewis, D. Superspreading drives the COVID pandemic — and could help to tame it. *Nature* **590**, 544–546 (2021).

42. Miller, S. L. *et al.* Transmission of SARS-CoV-2 by inhalation of respiratory aerosol in the Skagit Valley Chorale superspreading event. *Indoor Air* **31**, 314–323 (2021).
43. Johansson, M. A. *et al.* SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. *JAMA Netw Open* **4**, e2035057 (2021).
44. Greenhalgh, T. *et al.* Ten scientific reasons in support of airborne transmission of SARS-CoV-2. *The Lancet* **397**, 1603–1605 (2021).
45. Nazaroff, W. W. Indoor aerosol science aspects of SARS-CoV-2 transmission. *Indoor Air* **32**, e12970 (2022).
46. Morawska, L. & Milton, D. K. It Is Time to Address Airborne Transmission of Coronavirus Disease 2019 (COVID-19). *Clinical Infectious Diseases* **71**, 2311–2313 (2020).
47. WHO. Transmission of SARS-CoV-2: implications for infection prevention precautions. *World Health Organization* <https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions> (2020).
48. WHO. Coronavirus disease (COVID-19): How is it transmitted? *World Health Organization* <https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-how-is-it-transmitted> (2021).
49. Port, J. R. *et al.* Increased small particle aerosol transmission of B.1.1.7 compared with SARS-CoV-2 lineage A in vivo. *Nat Microbiol* **7**, 213–223 (2022).
50. Abkarian, M., Mendez, S., Xue, N., Yang, F. & Stone, H. A. Speech can produce jet-like transport relevant to asymptomatic spreading of virus. *Proc Natl Acad Sci U S A* **117**, 25237–25245 (2020).

51. Bourouiba, L., Dehandschoewercker, E. & Bush, J. W. M. Violent expiratory events: on coughing and sneezing. *Journal of Fluid Mechanics* **745**, 537–563 (2014).
52. Zhdanov, V. P. & Kasemo, B. Virions and respiratory droplets in air: Diffusion, drift, and contact with the epithelium. *Biosystems* **198**, 104241 (2020).
53. Chen, W., Zhang, N., Wei, J., Yen, H.-L. & Li, Y. Short-range airborne route dominates exposure of respiratory infection during close contact. *Building and Environment* **176**, 106859 (2020).
54. Bazant, M. Z. & Bush, J. W. M. A guideline to limit indoor airborne transmission of COVID-19. *Proc Natl Acad Sci U S A* **118**, e2018995118 (2021).
55. Vernez, D., Schwarz, S., Sauvain, J.-J., Petignat, C. & Suarez, G. Probable aerosol transmission of SARS-CoV-2 in a poorly ventilated courtroom. *Indoor Air* **31**, 1776–1785 (2021).
56. Wells, W. F. *Airborne Contagion and Air Hygiene*. (Harvard University Press, 1955).
57. Riley, E. C., Murphy, G. & Riley, R. L. Airborne spread of measles in a suburban elementary school. *Am J Epidemiol* **107**, 421–432 (1978).
58. Sze To, G. N. & Chao, C. Y. H. Review and comparison between the Wells–Riley and dose-response approaches to risk assessment of infectious respiratory diseases. *Indoor Air* **20**, 2–16 (2010).
59. Li, H. *et al.* Environmental Surveillance and Transmission Risk Assessments for SARS-CoV-2 in a Fitness Center. *Aerosol Air Qual. Res.* **21**, 210106 (2021).
60. Verma, R. *et al.* Variation in Severe Acute Respiratory Syndrome Coronavirus 2 Bioaerosol Production in Exhaled Breath. *Open Forum Infectious Diseases* **9**, ofab600 (2022).

61. Earnest, R. *et al.* Comparative transmissibility of SARS-CoV-2 variants Delta and Alpha in New England, USA. 2021.10.06.21264641 (2021) doi:10.1101/2021.10.06.21264641.
62. Teyssou, E. *et al.* The Delta SARS-CoV-2 variant has a higher viral load than the Beta and the historical variants in nasopharyngeal samples from newly diagnosed COVID-19 patients. *J Infect* **83**, e1–e3 (2021).
63. Li, B. *et al.* Viral infection and transmission in a large, well-traced outbreak caused by the SARS-CoV-2 Delta variant. *Nat Commun* **13**, 460 (2022).
64. Grant, R. *et al.* Impact of SARS-CoV-2 Delta variant on incubation, transmission settings and vaccine effectiveness: Results from a nationwide case-control study in France. *The Lancet Regional Health – Europe* **13**, (2022).
65. Lauer, S. A. *et al.* The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. *Ann Intern Med* **172**, 577–582 (2020).
66. Jansen, L. *et al.* Investigation of a SARS-CoV-2 B.1.1.529 (Omicron) Variant Cluster — Nebraska, November–December 2021. *MMWR Morb. Mortal. Wkly. Rep.* **70**, 1782–1784 (2021).
67. US EPA. What is a HEPA filter? *United States Environmental Protection Agency* <https://www.epa.gov/indoor-air-quality-iaq/what-hepa-filter-1> (2019).
68. Curtius, J., Granzin, M. & Schrod, J. Testing mobile air purifiers in a school classroom: Reducing the airborne transmission risk for SARS-CoV-2. *Aerosol Science and Technology* **55**, 586–599 (2021).

69. Duill, F. F. *et al.* The Impact of Large Mobile Air Purifiers on Aerosol Concentration in Classrooms and the Reduction of Airborne Transmission of SARS-CoV-2. *Int J Environ Res Public Health* **18**, 11523 (2021).
70. Jiang, S.-Y., Ma, A. & Ramachandran, S. Negative Air Ions and Their Effects on Human Health and Air Quality Improvement. *Int J Mol Sci* **19**, 2966 (2018).
71. Uk Lee, B., Yermakov, M. & Grinshpun, S. A. Removal of fine and ultrafine particles from indoor air environments by the unipolar ion emission. *Atmospheric Environment* **38**, 4815–4823 (2004).
72. Sawant, V. S., Meena, G. S. & Jadhav, D. B. Effect of Negative Air Ions on Fog and Smoke. *Aerosol Air Qual. Res.* **12**, 1007–1015 (2012).
73. Grinshpun, S. A. *et al.* Evaluation of ionic air purifiers for reducing aerosol exposure in confined indoor spaces. *Indoor Air* **15**, 235–245 (2005).
74. Wang, X., Ferro, E. G., Zhou, G., Hashimoto, D. & Bhatt, D. L. Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers. *JAMA* **324**, 703–704 (2020).
75. Li, X. *et al.* Wearing time and respiratory volume affect the filtration efficiency of masks against aerosols at different sizes. *Environ Technol Innov* **25**, 102165 (2022).
76. National Personal Protective Technology Laboratory. The Respiratory Protection Information Trusted Source. *Centers for Disease Control and Prevention* https://www.cdc.gov/niosh/npptl/topics/respirators/disp_part/respsource3basic.html (2021).
77. Basu, S. Computational characterization of inhaled droplet transport in the upper airway leading to SARS-CoV-2 infection. 2020.07.27.20162362 (2020)
doi:10.1101/2020.07.27.20162362.

78. Wang, D. *et al.* Population Bottlenecks and Intra-host Evolution During Human-to-Human Transmission of SARS-CoV-2. *Front. Med.* **8**, (2021).
79. Watanabe, T., Bartrand, T. A., Weir, M. H., Omura, T. & Haas, C. N. Development of a dose-response model for SARS coronavirus. *Risk Anal* **30**, 1129–1138 (2010).
80. Nikitin, N., Petrova, E., Trifonova, E. & Karpova, O. Influenza virus aerosols in the air and their infectiousness. *Adv Virol* **2014**, 859090 (2014).
81. Lythgoe, K. A. *et al.* SARS-CoV-2 within-host diversity and transmission. *Science* (2021) doi:10.1126/science.abg0821.
82. Martin, M. A. & Koelle, K. Comment on “Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2”. *Science Translational Medicine* **13**, eabh1803.
83. Abu-Raddad, L. J., Chemaitelly, H. & Butt, A. A. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *New England Journal of Medicine* **385**, 187–189 (2021).
84. Moss, P. The T cell immune response against SARS-CoV-2. *Nat Immunol* **23**, 186–193 (2022).
85. Cromer, D. *et al.* Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. *Lancet Microbe* **3**, e52–e61 (2022).
86. Vella, F. *et al.* Transmission mode associated with coronavirus disease 2019: a review. *Eur Rev Med Pharmacol Sci* **24**, 7889–7904 (2020).

87. Cheng, H.-Y. *et al.* Contact Tracing Assessment of COVID-19 Transmission Dynamics in Taiwan and Risk at Different Exposure Periods Before and After Symptom Onset. *JAMA Intern Med* **180**, 1156–1163 (2020).
88. Novazzi, F., Taborelli, S., Baj, A., Focosi, D. & Maggi, F. Asymptomatic SARS-CoV-2 Vaccine Breakthrough Infections in Health Care Workers Identified Through Routine Universal Surveillance Testing. *Ann Intern Med* M21-3486 (2021) doi:10.7326/M21-3486.
89. Rovida, F. *et al.* SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. *Nat Commun* **12**, 6032 (2021).
90. Riemersma, K. K. *et al.* Shedding of Infectious SARS-CoV-2 Despite Vaccination. 2021.07.31.21261387 (2021) doi:10.1101/2021.07.31.21261387.
91. Williams, L. R., Ferguson, N. M., Donnelly, C. A. & Grassly, N. C. Measuring vaccine efficacy against infection and disease in clinical trials: sources and magnitude of bias in COVID-19 vaccine efficacy estimates. 2021.07.30.21260912 (2021) doi:10.1101/2021.07.30.21260912.
92. Lin, D.-Y., Gu, Y., Zeng, D., Janes, H. E. & Gilbert, P. B. Evaluating Vaccine Efficacy Against SARS-CoV-2 Infection. 2021.04.16.21255614 (2021) doi:10.1101/2021.04.16.21255614.
93. Andrews, N. *et al.* Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. *New England Journal of Medicine* (2022) doi:10.1056/NEJMoa2119451.
94. Widge, A. T. *et al.* Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. *N Engl J Med* **384**, 80–82 (2021).

95. Notarte, K. I. *et al.* Characterization of the significant decline in humoral immune response six months post-SARS-CoV-2 mRNA vaccination: A systematic review. *J Med Virol* (2022) doi:10.1002/jmv.27688.
96. Khoury, D. S. *et al.* Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* **27**, 1205–1211 (2021).
97. Chemaitelly, H. *et al.* Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. *New England Journal of Medicine* **385**, e83 (2021).
98. Levin, E. G. *et al.* Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. *New England Journal of Medicine* **385**, e84 (2021).
99. Schubert, M. *et al.* Human serum from SARS-CoV-2-vaccinated and COVID-19 patients shows reduced binding to the RBD of SARS-CoV-2 Omicron variant. *BMC Med* **20**, 102 (2022).
100. Wall, E. C. *et al.* Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. *Lancet* **397**, 2331–2333 (2021).
101. Cele, S. *et al.* Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. *Nature* **602**, 654–656 (2022).
102. Carreño, J. M. *et al.* Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. *Nature* **602**, 682–688 (2022).
103. Lucas, C. *et al.* Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. *Nature* **600**, 523–529 (2021).
104. Davis, C. *et al.* Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. *PLoS Pathog* **17**, e1010022 (2021).

105. Garcia-Beltran, W. F. *et al.* Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. *Cell* **184**, 2372–2383.e9 (2021).
106. Buchan, S. A. *et al.* Effectiveness of COVID-19 vaccines against Omicron or Delta symptomatic infection and severe outcomes. 2021.12.30.21268565 (2022) doi:10.1101/2021.12.30.21268565.
107. Lefèvre, B. *et al.* Beta SARS-CoV-2 variant and BNT162b2 vaccine effectiveness in long-term care facilities in France. *The Lancet Healthy Longevity* **2**, e685–e687 (2021).
108. Abu-Raddad, L. J. *et al.* Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections. 2021.07.28.21261086 (2021) doi:10.1101/2021.07.28.21261086.
109. Acharya, C. B. *et al.* No Significant Difference in Viral Load Between Vaccinated and Unvaccinated, Asymptomatic and Symptomatic Groups When Infected with SARS-CoV-2 Delta Variant. 2021.09.28.21264262 (2021) doi:10.1101/2021.09.28.21264262.
110. Chia, P. Y. *et al.* Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study. *Clinical Microbiology and Infection* **0**, (2021).
111. Kissler, S. M. *et al.* Viral Dynamics of SARS-CoV-2 Variants in Vaccinated and Unvaccinated Persons. *New England Journal of Medicine* **385**, 2489–2491 (2021).
112. Boucau, J. *et al.* Duration of viable virus shedding in SARS-CoV-2 omicron variant infection. *medRxiv* 2022.03.01.22271582 (2022) doi:10.1101/2022.03.01.22271582.
113. Lyngse, F. P. *et al.* SARS-CoV-2 Omicron VOC Transmission in Danish Households. 2021.12.27.21268278 (2021) doi:10.1101/2021.12.27.21268278.

114. Brandal, L. T. *et al.* Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. *Eurosurveillance* **26**, (2021).
115. Brown, C. M. *et al.* Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings — Barnstable County, Massachusetts, July 2021. *MMWR Morb. Mortal. Wkly. Rep.* **70**, 1059–1062 (2021).
116. Levine-Tiefenbrun, M. *et al.* Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2. *Nat Med* **27**, 2108–2110 (2021).
117. Kuhlmann, C. *et al.* Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. *Lancet* **399**, 625–626 (2022).
118. Levine-Tiefenbrun, M. *et al.* Waning of SARS-CoV-2 booster viral-load reduction effectiveness. *Nat Commun* **13**, 1237 (2022).

Supplementary Figures





Figure S1: Viral concentrations in a room after the infected individual leaves. The concentration of SARS-CoV-2 in room air is initially at steady state. **A:** Infected individual with Wuhan strain of virus, **B:** Individual infected with Omicron variant. **C:** Individual infected with Delta variant. In all panels, the blue curve shows the concentration when there is no ventilation in the room, the orange curve shows the concentration when there is 2 air exchanges/hr, and the green curve shows the concentration when there is 6 air exchanges/hr.

A**B**

Parameter name	Value
Classroom size	4000 cubic feet
Low viral load emission rate	5000 virions/hr
Intermediate viral load emission rate	4,307,619 virions/hr
High viral load emission rate	5,000,000 virions/hr
Viral particle lifetime	1.6 hr
# of virions needed to initiate infection	500
Respiratory tidal volume	0.5 L
Respiratory rate	15 breaths/min

Figure S2: Modeling approach to estimate transmission risk in the classroom. **A:** Model schematic. **B:** Table of parameter values used in differential equations model simulating SARS-CoV-2 emission and inhalation in classrooms.

Supplementary Tables

Droplet size (μm)	Percent of expelled droplets	Deposition probability
0.10	0.16	1.34
0.20	0.16	1.60
0.30	0.16	1.53
0.40	0.16	1.51
0.50	0.16	1.47
0.60	0.16	1.47
0.70	0.16	1.52
0.80	0.16	1.52
0.90	0.16	1.48
1.00	0.16	1.43
1.50	0.16	1.74
2.00	0.16	1.98
2.50	0.16	2.49
3.00	0.16	2.82
3.50	0.16	3.70
4.00	0.16	4.77
4.50	0.16	5.61
5.00	2.44	5.97
6.00	2.44	6.71
7.00	2.44	6.09
8.00	2.44	5.36
9.00	2.44	4.69
10.00	1.70	4.07
11.00	1.70	3.54
12.00	1.70	3.09
13.00	1.70	2.94
14.00	1.70	2.73
15.00	0.90	2.18
16.00	0.90	1.55
17.00	0.90	1.23
18.00	0.90	0.78
19.00	0.90	0.73
20.00	0.78	0.52
21.00	0.78	0.41
22.00	0.78	0.29
23.00	0.78	0.17
24.00	0.78	0.07
25.00	0.84	0.01
26.00	0.84	0.00
27.00	0.84	0.01
28.00	0.84	0.00
29.00	0.84	0.00
30.00	0.88	0.00

Table S1: Estimating the fraction of inhaled viruses that are deposited in the nasopharynx based on CFD results.